CardioStabil XR

HFrEF

Product Name CardioStabil XR

Generic Name cardiostabilib

Approved Indication HFrEF

Therapeutic Area Cardiovascular

Manufacturer PurePharma Inc.

1. 32% reduction in CV death/HF hospitalization vs. placebo

2. Demonstrated renal protective effects

3. Flexible dosing with simple titration

Profile Status

Complete

Therapeutic Area

Cardiovascular

Quick Stats

32% reduction in CV death/HF hospitalization

Key Claim: 32% reduction in CV death/HF hospitalization

Trial: STABILIZE-HF (n=4,200)

No black box warning. Common AEs: Dizziness 8%, Fatigue 6%, Hypotension 5%

50mg BID → 100mg BID, titrate q2 weeks

$450/month AWP

Competitive landscape data available.